Excerpts

Moreover, trials focused on high-risk MM patients demonstrated a marginally statistically significant ( p = 0.04) lower PFS rate (79% PFS%, 95% CI: 72–85%) than trials on standard MM populations (87% PFS%, 95% CI: 82–91%) ( Supplementary Table S1 ).

Age at diagnosis was partially significant between R and NR ( p -value = 0.04), while TMB differed significantly (mean log2 (TMB+1): 3.14 versus 4.03, p -value < 0.0001).

However, the marginal significance ( p -value = 0.04) limits the value of this module.

Although most gastrointestinal symptoms did not reach statistical significance, early satiety ( p = 0.041) and functional deterioration ( p = 0.039) were significantly associated with irinotecan administration, while nausea ( p = 0.089) and vomiting ( p = 0.087) showed trends toward significance.

A near-significant separation was observed for Model 2 ( p = 0.041), whereas the clinical factor-only model (Model 3) failed to achieve significance ( p = 0.29).

This between-treatment difference in OS approached significance in the PAS (median OS 180 vs. 83 days, respectively; HR 0.39; p = 0.042) ( Figure 5 ).

The correlation between BMI and V/S ratio had marginal significance (Spearman R = 0.14, p = 0.042). 2.3.

However, only two of these associations were marginally significant: in high grade (pG3) tumors (OR, 0.54; 95% c.i., 0.29–1.00; p = 0.042), and in PR negative tumors (OR, 0.58; 95% c.i., 0.33–1.01; p < 0.05; Figure 2 ). 2.5.

Individual immune components did not show significant linear correlations with RGR; on median-split stratification, high B7-H3-positive tumor cell density was associated with a nominally significant difference in RGR ( p = 0.0428, unadjusted).

We observed that patients in the high acid adaptation similarity group had a weakly significant average lower age than remaining patients (two-sided t -test, p = 0.043, means 58.99 and 62.15) ( Figure 4 D( i )).

Surprisingly, higher T-stage lowered the risk, although with a borderline significance ( p = 0.043).

CR models also indicated that R-IPI was barely significant as a prognostic factor for refractory- or relapse-related death (sHR = 2.8, p = 0.043; sHR = 10.03, p = 0.043, respectively).

Beta diversity analysis showed marginally significant differences in microbial community composition at the family level (F = 2.251, p = 0.044, FDR = 0.051), but not at genus or species levels ( Figure S11b ).

In contrast, at 24 months assessment, higher mRNA E6 & E7 positivity rates were documented in both groups (6.3%/10% NASBA/flow outcomes, and 17.8%/18.3% NASBA/flow results), a finding marginally significant ( p = 0.0448) when considering the NASBA method but insignificant for the flow approach.

Furthermore, patients without liver metastasis demonstrated a significantly improved PFS (HR = 0.59, p = 0.027), and a borderline significant benefit was also seen in patients with liver metastasis (HR = 0.4, p = 0.045).

Gender showed a trend toward better OS for females, reaching significance for PnI patients (HR 0.75, p = 0.045), but not for LVI individuals (HR 0.80, p = 0.12).

On the other hand, the tremelimumab arm did not reach statistical significance with median OS of 10.4 months vs. 10.5 months with chemotherapy alone (HR 0.82, 95% CI 0.68–1.00, p = 0.0451).

The difference in the number of released proteins between the two yellow/upper subclusters reached only borderline significance ( p = 0.0455), the patients in the bright yellow upper subcluster showing reduced release especially of proteins in the middle right brown protein clusters (exosomal/extracellular and nuclear proteins).

In contrast, there was no difference in distant cancer recurrence between patients with or without CTA-expression in TFL in the discovery cohort, while in the validation cohort the difference in distant cancer recurrence between patients with and without CTA-expression in TFL was small and borderline significant ( p = 0.046) ( Figure S6 ).

On the other hand, chemotherapy plus pembrolizumab was not formally superior to chemotherapy alone in terms of OS even if a favorable trend was seen both in CPS ≥ 1% (mOS 12.5 vs. 11.1 months, HR: 0.85, p = 0.046) and CPS ≥ 10% (mOS 12.3 vs. 10.8, HR: 0.85, p = 0.158) patients.

The association between GCTTC haplotype non-carriers and advanced tumor size showed a trend towards significance (OR = 0.380, 95% CI: 0.166–0.869, p = 0.046).

Pairwise Mann–Whitney U tests identified a marginally significant difference between Grade II and Grade IV cytology results ( p = 0.046), but no other inter-group comparisons reached statistical significance.

For VFI, the difference was borderline significant ( p = 0.046) ( Figure 5 ).

Tumor grading showed nearly significant differences, with grade 2 tumors carrying a worse prognosis than grade 3 ( p = 0.046).

Although a nominally significant difference was found between Grade II and Grade IV ( p = 0.0466), this did not remain significant after Bonferroni correction.